3 Stocks to Buy and Hold for 2026 and Beyond

By Justin Pope – Feb 19, 2026 at 12:15PM ESTKey PointsAbbVie is a Dividend King, poised for strong growth with Rinvoq and Skyrizi.Eli Lilly has taken control of the obesity drug market, with major possibilities ahead.Bristol Myers Squibb looks ready to ride its oncology portfolio to massive investment returns.We’re bullish on these 10 stocks ›NYSE: ABBVAbbVieMarket Cap$404BToday's Changeangle-down(-1.89%) $4.32Current Price$224.40Price as of February 19, 2026 at 1:53 PM ETAny of these three pharmaceutical titans could move the needle in your portfolio.Healthcare is a multi-trillion-dollar industry in the United States alone. With 2024 spending exceeding $5.3 trillion, the sector is nearly one-fifth of the U.S. economy. That alone justifies holding several healthcare stocks in your long-term portfolio, though it can be intimidating given the industry-wide regulatory and political pressures that constantly generate headlines. It's usually wise to stick to industry leaders with entrenched businesses and a proven record of navigating the industry's various twists and turns. Here are three excellent healthcare stocks that investors should consider buying for 2026 and beyond. Image source: Getty Images. 1. AbbVie Pharmaceutical giant AbbVie (ABBV 1.89%) is an industry heavyweight. It boasts a diverse portfolio of treatments for conditions across immunology, neuroscience, oncology, aesthetics, and eye care. AbbVie has evolved and rebuilt its pipeline throughout its decades-long history, a crucial ability for a pharmaceutical company since drug patents eventually expire. ExpandNYSE: ABBVAbbVieToday's Change(-1.89%) $-4.32Current Price$224.40Key Data PointsMarket Cap$404BDay's Range$223.02 - $229.3852wk Range$164.39 - $244.81Volume95KAvg Vol6.6MGross Margin83.38%Dividend Yield2.91% AbbVie offers a solid 3% dividend yield at its current share price. The stock is also a Dividend King, meaning it has increased its dividend for at least 50 consecutive years, another testament to its ability to adapt to change. AbbVie is entering a new growth phase, thanks to blockbuster drugs Rinvoq and Skyrizi. Analysts anticipate that the company will grow earnings by more than 17% annually over the long term. 2.

Eli Lilly Another pharmaceutical leader, Eli Lilly (LLY 0.11%), offers investors a strong foothold in the obesity drug market. Morgan Stanley estimates that the market could reach $144 billion by the end of the decade. Eli Lilly has become the industry leader thanks to tirzepatide, the key drug in Mounjaro and Zepbound, which has taken market share from archrival Novo Nordisk. ExpandNYSE: LLYEli LillyToday's Change(-0.11%) $-1.09Current Price$1019.47Key Data PointsMarket Cap$963BDay's Range$1007.27 - $1020.9852wk Range$623.78 - $1133.95Volume43KAvg Vol3.3MGross Margin83.04%Dividend Yield0.61% On top of that, Eli Lilly has a robust pipeline. It's gearing up for an imminent FDA approval and launch of orforglipron, its first oral GLP-1 agonist. Additionally, experts believe that its next-generation drug, a triple agonist called Retatrutide, could become one of the best sellers in history, given its strong performance in clinical trials to date. Wall Street anticipates nearly 25% annualized earnings growth from Eli Lilly over the long term, making the stock an obvious buy-and-hold candidate. 3.

Bristol Myers Squibb Bristol Myers Squibb (BMY +0.68%) is currently facing patent expirations on several of its top products over the coming years. This includes top sellers Eliquis and Opdivo, which could face generic competition within the next couple of years. However, the company's big momentum in oncology powered a strong fourth-quarter earnings report, and Bristol Myers Squibb has a solid pipeline with a laundry list of upcoming milestones. ExpandNYSE: BMYBristol Myers SquibbToday's Change(0.68%) $0.41Current Price$60.13Key Data PointsMarket Cap$122BDay's Range$59.23 - $60.3652wk Range$42.52 - $63.33Volume6.2MAvg Vol14MGross Margin65.89%Dividend Yield4.17% If Bristol Myers Squibb can continue to replenish its business with new and growing drugs, the stock could generate impressive total returns from here. Shares already offer a 4% dividend yield and trade at just 10 times forward earnings estimates. Analysts see the company growing earnings by 15% annually over the long term, so there is a ton of upside potential as long as Bristol Myers Squibb can successfully bring its pipeline drugs to market.Read NextFeb 18, 2026 •By Mark Roussin, CPA6 Forever Dividend StocksFeb 15, 2026 •By Prosper Junior Bakiny1 No-Brainer Dividend Stock to Buy on the DipFeb 14, 2026 •By Dave Kovaleski2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-OffFeb 12, 2026 •By Keith Speights1 Reason I'm Never Selling AbbVie StockFeb 3, 2026 •By James Halley2 Healthcare Dividend Stocks That are Just What the Doctor OrderedFeb 2, 2026 •By Keith SpeightsWhere Will AbbVie Be in 5 Years?About the AuthorJustin Pope is a contributing Motley Fool stock market analyst covering information technology, consumer discretionary, consumer staples, and industrials. Prior to The Motley Fool, Justin was a business manager for an industrial company.TMFbeardedFiStocks MentionedAbbVieNYSE: ABBV$224.40 (1.89%) $4.32Morgan StanleyNYSE: MS$173.22 (1.91%) $3.37Bristol Myers SquibbNYSE: BMY$60.13 (+0.68%) $+0.41Eli LillyNYSE: LLY$1019.17 (0.14%) $1.39*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.